REPORT ID 3180

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Professional Survey Report 2017

Publish Date
12-Dec-17
Pages
115
Format
Electronic (PDF)

This report studies B-Cell Maturation Antigen(BCMA) Targeted Therapies in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
    Transposagen Biopharmaceuticals
    Sutro Biopharma
    Malin Corporation
    Eureka Therapeutics
    firstVentury Equity
    Five Prime Therapeutics
    Credit Suisse Securities
    Dana-Farber Cancer Institute
    Deerfield Partners
    Onyx Pharmaceuticals
    Juno Therapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Bispecific Antibodies
    Antibody Drug Conjugates
    Chimeric Antigen Receptor T-Cells

By Application, the market can be split into
    Liver Cancer
    Respiratory Cancer
    Brain Cancer
    Others

By Regions, this report covers (we can add the regions/countries as you want)
    North America
    China
    Europe
    Southeast Asia
    Japan
    India

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Professional Survey Report 2017
1 Industry Overview of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    1.1 Definition and Specifications of B-Cell Maturation Antigen(BCMA) Targeted Therapies
        1.1.1 Definition of B-Cell Maturation Antigen(BCMA) Targeted Therapies
        1.1.2 Specifications of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    1.2 Classification of B-Cell Maturation Antigen(BCMA) Targeted Therapies
        1.2.1 Bispecific Antibodies
        1.2.2 Antibody Drug Conjugates
        1.2.3 Chimeric Antigen Receptor T-Cells
    1.3 Applications of B-Cell Maturation Antigen(BCMA) Targeted Therapies
        1.3.1 Liver Cancer
        1.3.2 Respiratory Cancer
        1.3.3 Brain Cancer
        1.3.4 Others
    1.4 Market Segment by Regions
        1.4.1 North America
        1.4.2 China
        1.4.3 Europe
        1.4.4 Southeast Asia
        1.4.5 Japan
        1.4.6 India

2 Manufacturing Cost Structure Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    2.1 Raw Material and Suppliers
    2.2 Manufacturing Cost Structure Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    2.3 Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    2.4 Industry Chain Structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies

3 Technical Data and Manufacturing Plants Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    3.1 Capacity and Commercial Production Date of Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
    3.2 Manufacturing Plants Distribution of Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
    3.3 R&D Status and Technology Source of Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
    3.4 Raw Materials Sources Analysis of Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016

4 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Overall Market Overview
    4.1 2012-2017E Overall Market Analysis
    4.2 Capacity Analysis
        4.2.1 2012-2017E Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Capacity and Growth Rate Analysis
        4.2.2 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Capacity Analysis (Company Segment)
    4.3 Sales Analysis
        4.3.1 2012-2017E Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate Analysis
        4.3.2 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Analysis (Company Segment)
    4.4 Sales Price Analysis
        4.4.1 2012-2017E Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price
        4.4.2 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis (Company Segment)

5 B-Cell Maturation Antigen(BCMA) Targeted Therapies Regional Market Analysis
    5.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.1.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.1.2 North America 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.1.3 North America 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.1.4 North America 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis
    5.2 China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.2.1 China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.2.2 China 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.2.3 China 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.2.4 China 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis
    5.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.3.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.3.2 Europe 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.3.3 Europe 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.3.4 Europe 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis
    5.4 Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.4.1 Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.4.2 Southeast Asia 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.4.3 Southeast Asia 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.4.4 Southeast Asia 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis
    5.5 Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.5.1 Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.5.2 Japan 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.5.3 Japan 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.5.4 Japan 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis
    5.6 India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Analysis
        5.6.1 India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
        5.6.2 India 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Local Supply, Import, Export, Local Consumption Analysis
        5.6.3 India 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Analysis
        5.6.4 India 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share Analysis

6 Global 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Segment Market Analysis (by Type)
    6.1 Global 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Type
    6.2 Different Types of B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Interview Price Analysis
    6.3 Different Types of B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Driving Factors Analysis
        6.3.1 Bispecific Antibodies of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis
        6.3.2 Antibody Drug Conjugates of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis
        6.3.3 Chimeric Antigen Receptor T-Cells of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis

7 Global 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Segment Market Analysis (by Application)
    7.1 Global 2012-2017E B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption by Application
    7.2 Different Application of B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Interview Price Analysis
    7.3 Different Application of B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Driving Factors Analysis
        7.3.1 Liver Cancer of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis
        7.3.2 Respiratory Cancer of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis
        7.3.3 Brain Cancer of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis
        7.3.4 Others of B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Driving Factor Analysis

8 Major Manufacturers Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    8.1 Transposagen Biopharmaceuticals
        8.1.1 Company Profile
        8.1.2 Product Picture and Specifications
            8.1.2.1 Product A
            8.1.2.2 Product B
        8.1.3 Transposagen Biopharmaceuticals 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.1.4 Transposagen Biopharmaceuticals 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.2 Sutro Biopharma
        8.2.1 Company Profile
        8.2.2 Product Picture and Specifications
            8.2.2.1 Product A
            8.2.2.2 Product B
        8.2.3 Sutro Biopharma 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.2.4 Sutro Biopharma 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.3 Malin Corporation
        8.3.1 Company Profile
        8.3.2 Product Picture and Specifications
            8.3.2.1 Product A
            8.3.2.2 Product B
        8.3.3 Malin Corporation 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.3.4 Malin Corporation 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.4 Eureka Therapeutics
        8.4.1 Company Profile
        8.4.2 Product Picture and Specifications
            8.4.2.1 Product A
            8.4.2.2 Product B
        8.4.3 Eureka Therapeutics 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.4.4 Eureka Therapeutics 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.5 firstVentury Equity
        8.5.1 Company Profile
        8.5.2 Product Picture and Specifications
            8.5.2.1 Product A
            8.5.2.2 Product B
        8.5.3 firstVentury Equity 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.5.4 firstVentury Equity 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.6 Five Prime Therapeutics
        8.6.1 Company Profile
        8.6.2 Product Picture and Specifications
            8.6.2.1 Product A
            8.6.2.2 Product B
        8.6.3 Five Prime Therapeutics 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.6.4 Five Prime Therapeutics 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.7 Credit Suisse Securities
        8.7.1 Company Profile
        8.7.2 Product Picture and Specifications
            8.7.2.1 Product A
            8.7.2.2 Product B
        8.7.3 Credit Suisse Securities 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.7.4 Credit Suisse Securities 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.8 Dana-Farber Cancer Institute
        8.8.1 Company Profile
        8.8.2 Product Picture and Specifications
            8.8.2.1 Product A
            8.8.2.2 Product B
        8.8.3 Dana-Farber Cancer Institute 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.8.4 Dana-Farber Cancer Institute 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.9 Deerfield Partners
        8.9.1 Company Profile
        8.9.2 Product Picture and Specifications
            8.9.2.1 Product A
            8.9.2.2 Product B
        8.9.3 Deerfield Partners 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.9.4 Deerfield Partners 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.10 Onyx Pharmaceuticals
        8.10.1 Company Profile
        8.10.2 Product Picture and Specifications
            8.10.2.1 Product A
            8.10.2.2 Product B
        8.10.3 Onyx Pharmaceuticals 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.10.4 Onyx Pharmaceuticals 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Region Distribution Analysis
    8.11 Juno Therapeutics

9 Development Trend of Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
    9.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Trend Analysis
        9.1.1 Global 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Volume and Value) Forecast
        9.1.2 Global 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price Forecast
    9.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Regional Market Trend
        9.2.1 North America 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
        9.2.2 China 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
        9.2.3 Europe 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
        9.2.4 Southeast Asia 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
        9.2.5 Japan 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
        9.2.6 India 2017-2022 B-Cell Maturation Antigen(BCMA) Targeted Therapies Consumption Forecast
    9.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Trend (Product Type)
    9.4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Trend (Application)

10 B-Cell Maturation Antigen(BCMA) Targeted Therapies Marketing Type Analysis
    10.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Regional Marketing Type Analysis
    10.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies International Trade Type Analysis
    10.3 Traders or Distributors with Contact Information of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Region
    10.4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Supply Chain Analysis

11 Consumers Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
    11.1 Consumer 1 Analysis
    11.2 Consumer 2 Analysis
    11.3 Consumer 3 Analysis
    11.4 Consumer 4 Analysis

12 Conclusion of the Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Professional Survey Report 2017
    Methodology
    Analyst Introduction
    Data Source